Neurological Disorder Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The neurological disorder drugs market size was valued at USD 98.12 billion in 2025 and estimated to grow from USD 105.44 billion in 2026 to reach USD 151.09 billion by 2031, at a CAGR of 7.46% during the forecast period (2026-2031). This report is Segmented by Indication (Alzheimer's Disease, Parkinson's Disease, and More), Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and More), Route of Administration (Oral, Intravenous, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Neurological Disorder Drugs Market Trends and Insights

Ageing Population & Rising Prevalence of CNS Disorders

Longer life expectancy is increasing the absolute number of patients with chronic neurological illnesses, a trend most visible in high-income economies where individuals aged ≥ 60 will represent more than 30% of the population by 2050. Europe already reports 6.9 million Alzheimer’s cases, a figure that could double before mid-century, prompting insurers to reimburse earlier and costlier interventions. Similar prevalence curves are appearing in Parkinson’s disease, epilepsy, and multiple sclerosis, allowing manufacturers that expand regional production to secure first-mover volume advantages. Governments are also financing preventive screening that paradoxically lifts diagnosed prevalence and enlarges the addressable pool for therapeutics. The direct economic burden is pushing regulators to accelerate approvals, tightening the feedback loop between scientific discovery and bedside adoption and thereby supporting sustained expansion of the neurological disorder drugs market.

Breakthrough Disease-Modifying Approvals Drive Market Confidence

Leqembi’s full approval and Donanemab’s positive Phase III data have proven that amyloid-targeting pathways can achieve clinical and commercial success, validating high-risk neurodegenerative targets. Revenue ramp-ups have signaled strong payer acceptance despite high list prices, emboldening capital markets to back next-generation disease-modifying candidates across Huntington’s disease, ALS, and frontotemporal dementia. The European Medicines Agency revised its earlier stance on Leqembi, highlighting regulators’ willingness to re-assess benefit-risk when unmet need is compelling. Companies are reacting by accelerating time-to-submission strategies and intensifying global Phase III enrolment, moves that shorten commercialization cycles and further enlarge the neurological disorder drugs market.

High Late-Stage Attrition & R&D Costs Create Development Barriers

Neurology maintains the lowest Phase III success rate among major therapeutic areas, hovering near 30% compared with 58% for oncology. Complex endpoints, placebo effects, and heterogeneous pathophysiology drive median program costs above USD 2 billion, throttling smaller companies reliant on single assets. Investors, still wary from high-profile Alzheimer’s failures, require co-development risk-sharing that dilutes upside. Large firms mitigate through diversified portfolios, but the absolute spend siphons resources from early exploratory programs, dampening near-term asset flow into the neurological disorder drugs industry.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Orphan-Drug Incentives Accelerates Rare-Disease Development
• AI-Enabled Neuro-Drug Discovery Transforms Pipeline Development
• Patent Cliff Pressures Intensify Competitive Dynamics

Segment Analysis

Alzheimer’s disease generated 28.67% of neurological disorder drugs market revenue in 2025 on the back of high-ticket disease-modifying launches. The platform is widening as payers approve biomarker-confirmed early-stage use, anchoring premium ASPs and elevating the overall neurological disorder drugs market size. In the same period, rare & orphan neurologic diseases grew fastest, advancing at an 8.01% CAGR owing to orphan-drug exclusivity and public-grant co-funding. The differential growth rates signal portfolio-balancing value: broad-based Alzheimer’s drugs produce predictable volume while smaller, high-exclusivity disorders deliver margin upside.

Pipeline readouts in Huntington’s and Rett syndrome illustrate how niche indications can pivot to non-dilutive financing, allowing firms to monetize science before peak-sales maturity. Across Parkinson’s and epilepsy, incremental innovation - such as extended-release L-dopa and third-generation sodium-channel blockers - sustains mid-single-digit growth but cedes relative share to high-impact disease-modifiers. Migraine continues its biologics-driven transformation, as CGRP inhibitors expand prophylaxis beyond triptan non-responders, reinforcing multi-brand coexistence under roomier clinical guidelines. Collectively, indication diversity hedges exposure to single-asset risk and keeps the neurological disorder drugs market on a stable expansion path.

Antiepileptics retained 24.01% of the neurological disorder drugs market share in 2025 thanks to entrenched prescribing patterns and broad insurance coverage. Their generics bulk still provides high patient volume, but revenue concentration is shifting as branded precision molecules secure orphan reimbursement. CGRP monoclonal antibodies, however, recorded the highest 8.29% CAGR, scaling an addressable pool of 36 million chronic migraine patients who previously cycled through four or more preventive classes.

Cholinesterase inhibitors and NMDA antagonists remain Alzheimer’s mainstays, yet real-world evidence indicates gradual slot replacement by Leqembi and Donanemab, reaffirming the transition from symptomatic to disease-modifying therapy. Dopamine agonists preserve relevance in Parkinson’s motor-symptom control, but non-motor endpoints drive demand for combination protocols. Immunomodulators, notably S1P receptor modulators, widen multiple-sclerosis remission durability, while biosimilar interferons introduce cost offsets that allow payors to fund novel agents. This compositional shift underscores how diversified drug-class dynamics reinforce resilience across the neurological disorder drugs market.

Complete Report Scope:

• By Indication
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Epilepsy
  • Multiple Sclerosis
  • Migraine
  • ADHD & Other Psychiatric CNS
  • Rare & Orphan Neurological Disorders
• By Drug Class
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Dopamine Agonists & Precursors
  • Antiepileptics
  • CGRP & Other Novel Biologics
  • Immunomodulators
  • Neuroprotective / Disease-Modifying Agents
• By Route of Administration
  • Oral
  • Intravenous
  • Intranasal
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America generated 39.35% of the neurological disorder drugs market size in 2025, underpinned by early uptake of FDA-approved disease-modifying agents and broad private-payer coverage. The region’s payer tolerance for premium therapies, combined with strong clinical-trial infrastructure, sustains double-digit launch trajectories for high-impact assets. Public policy also fuels demand: Medicare’s revised coverage decision for amyloid-targeting drugs effectively opens a multi-billion-dollar reimbursement channel, accelerating top-line momentum for asset holders.

Europe follows as the second-largest arena, though its reimbursement committees mandate cost-effectiveness thresholds that temper launch pricing. The EMA’s conditional endorsements typically require real-world evidence collection, compelling manufacturers to run outcome registries that can be leveraged globally. Despite tighter price discipline, pan-EU orphan-drug incentives - ten-year exclusivity and R&D tax credits - create vibrant sub-markets for rare neurological indications. Digital-health pilots in Germany’s DiGA program and France’s ETAPES tele-monitoring scheme are catalyzing remote-care integration, indirectly boosting prescription fills through adherence tools.

Asia-Pacific is the fastest-growing cluster, advancing at a 8.70% CAGR thanks to rapid urbanization, rising incomes, and regulatory harmonization. China’s National Reimbursement Drug List now incorporates several foreign neurological biologics, substantially reducing patient copays and unlocking volume. Japan’s Sakigake pathway continues to entice global developers with expedited review, while Australia’s Therapeutic Goods Administration aligns labeling changes within weeks of FDA actions, streamlining regional launches. Local manufacturing incentives in India and South Korea attract CDMO investment, shortening supply chains and building indigenous capacity that keeps margin erosion under control. The collective momentum positions Asia-Pacific as a strategic focal point for scaling the neurological disorder drugs market over the next decade.

List of Companies Covered in this Report:

• Biogen
• Pfizer
• Novartis
• Johnson & Johnson
• Eli Lilly and Company
• Merck
• Roche
• Takeda Pharmaceuticals
• Eisai
• Abbvie
• Teva Pharmaceutical Industries
• UCB
• Lundbeck
• Sanofi
• Amgen
• Jazz Pharmaceuticals
• Neurocrine Biosciences
• Acadia Pharmaceuticals
• Sage Therapeutics
• Sunovion (Sumitomo)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support